[1] Naji, N., Nasir, I., Beshtawi, M., Mohammed, B., Admour, I., Mahmood, S.A., Zaman, Q. and Dham, R. (2002) Bioequivalence Evaluation of Two Brands of Gliclazide 80 mg Tablets (Gliclazide and Diamicron) in Healthy Human Volunteers. Biopharmaceutics and Drug Disposition, 23, 197-202.
http://dx.doi.org/10.1002/bdd.310
[2] Hong, S.S., Lee, S.H., Lee, Y.J., Chung, S.J., Lee, M.H. and Shim, C.K. (1998) Accelerated Oral Absorption of Gliclazide in Human Subjects from a Soft Gelatin Capsule Containing a PEG 400 Suspension of Gliclazide. Journal of Controlled Release, 51, 185-192.
http://www.dx.doi.org/10.1016/S01683659(97)00167-3
[3] Delrat, P., Paraire, M. and Jochemsen, R. (2002) Complete Bioavailability and Lack of Food-Effect on Pharmacokinetics of Gliclazid 30 mg Modified Release in Healthy Volunteers. Biopharmaceutics & Drug Disposition, 23, 151-157.
http://www.dx.doi.org/10.1002/dbb.303
[4] Barochez, B.H.D., Wuthrich, P. and Martin, L. (2004) Core Tablet for Controlled Release of Gliclazide after Oral Administration. US Patent No: 6733782.
[5] Murpani, D. and Madan, A. (2006) Modified Release Formulation of Gliclazide. US Patent Application WO 2006/ 123213 A1.
[6] Wit, J.B. and Doshi, H.A. (2006) Sustained-Release Formulation of Gliclazide. European Patent Application 2181705.
[7] Jin, X., Zhang, Y., Xaio, L. and Zhao, Z. (2008) Optimization of Extended Zero-Order Release Gliclazide Tablets Using D-Optimal Mixture Design. Yakugaku Zasshi, 128, 1475-1483. http://www.dx.doi.org/10.1248/yakushi.128.1475
[8] Raja Rajeswari, K., Abbulu, K., Sudhakar, M. and Ravi, N. (2011) Formulation and in Vitro Evaluation of Hydrogel Matrices of Gliclazide Modified Release Tablets. International Journal of Pharmacy, 1, 82-87.
[9] Srivastav, M., Prabharkar, B. and Omray, A. (2011) Effect of Alkaline Excipients on the Release Profile of Gliclazide Extended Release Tablets. Journal of Pharmaceutical Science and Technology, 3, 462-470.
[10] Vijayalakshmi, P., Devi, V.K., Narendra, C. and Srinagesh, S. (2008) Development of Extended Zero-Order Release Gliclazide Tablets by Central Composite Design. Drug Development and Industrial Pharmacy, 34, 33-45.
http://dx.doi.org/10.1080/0363904071386129
[11] Jeyaprabha, P., Sudhamani, T., Mahendra, H., Ganesan, V. and Senthil, S.P. (2010) Formulation and Evaluation of Gliclazide Modified Release Tablets Using Hydroxypropyl Cellulose. International Research Journal of Pharmacy, 1, 282-287.
[12] Li, W., Du, G., Yang, Z., Zhang, Z., Nie, S., Peng, B. and Pan, W. (2008) In Vitro and in Vivo Evaluation of a Novel Push-Pull Osmotic Pump with Orifices on Both Surfaces. Drug Development and Industrial Pharmacy, 34, 1350-1355.
http://www.dx.doi.org/10.1080/10673220802122928
[13] Kumar, M.S., Ramakrishna, R. and Kumar, N.N. (2010) Design and Development of Oral Controlled Release Formulations of Gliclazide Using Natural Polymers. International Research Journal of Pharmacy, 1, 233-242.
[14] Devarajan, P.V. and Sonavane, G.S. (2007) Preparation and in Intro/in Vivo Evaluation of Gliclazide Loaded Eudragit Nanoparticles as a Sustained Release Carrier. Drug Development and Industrial Pharmacy, 33, 101-111.
http://www.dx.doi.org/10.1080/03639040601096695
[15] Varshosaz, J., Tavakoli, N., Minayian, M. and Rahdari, N. (2009) Applying the Taguchi Design for Optimized Formulation of Sustained Release Gliclazide Chitosan Beads an in Vitro/in Vivo Study. AAPS PharmSciTech, 10, 158-164.
http://www.dx.doi.org/10.1208/s12249-009-9191-8
[16] Barakat, N.S. and Almurshedi, A.S. (2010) Design and Development of Gliclazide-Loaded Chitosan Microparticles for Oral Sustained Drug Delivery: In Vitro/in Vivo Evaluation. Journal of Pharmacy and Pharmacology, 62, 169-178.
http://www.dx.doi.10.1111/j.2042-7158.2010.01214.x
[17] Wang, L., Wang, J., Lin, X. and Tang, X. (2010) Preparation and in Vitro Evaluation of Gliclazide Sustained-Release Matrix Pellets: Formulation and Storage Stability. Drug Development and Industrial Pharmacy, 36, 814-822.
http://www.dx.doi.org/10.3109/03639040903520967
[18] Hussain, T., Saeed, T., Mumtaz, A.M., Javid, Z., Abbas, K., Awais, A. and Idrees, H.A. (2013) Effect of Two Hydrophobic Polymers on the Release of Gliclazide from Their Matrix Tablets. ACTA Poloniae Pharmaceutica-Drug Research, 70, 749-757.
[19] Kumar, C.S., Reddy-Budidti, K.K., Battula, S.P. and Ayyavala, C.S. (2013) Formulation and Evaluation of Ficusglomerata Mucilage Sustained Release Matrix Tablets. Pakistan Journal of Pharmaceutical Sciences, 24, 399-404.
[20] Costa, P. and Manuel, J. (2001) Modeling and Comparison of Dissolution Profiles. European Journal of Pharmaceutical Science, 13, 123-133.
http://www.dx.doi.org/10.1016/S0928-0987(01)00095-1
[21] Badgujar, P. and Shaikh, T. (2013) Development of Dissolution Media for Marketed Gliclazide Modified Release Tablets. Pharma Sience Monitor, 4, 35-363.